TD Cowen Boosts Danaher (NYSE:DHR) Price Target to $290.00

Danaher (NYSE:DHR) had its price objective raised by investment analysts at TD Cowen from $280.00 to $290.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the conglomerate’s stock. TD Cowen’s price target would indicate a potential upside of 15.82% from the company’s current price.

Several other analysts have also issued reports on DHR. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and increased their price objective for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Barclays upped their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday. Royal Bank of Canada boosted their price objective on Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Finally, Raymond James increased their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $269.38.

Danaher Stock Down 1.1 %

Shares of Danaher stock traded down $2.72 on Wednesday, reaching $250.39. 1,285,176 shares of the company were exchanged, compared to its average volume of 2,757,865. Danaher has a one year low of $182.09 and a one year high of $259.00. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average of $248.95 and a 200 day moving average of $230.64. The company has a market capitalization of $185.42 billion, a price-to-earnings ratio of 39.15, a PEG ratio of 3.96 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.36 earnings per share. On average, equities research analysts forecast that Danaher will post 7.62 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Daniel Raskas sold 23,757 shares of Danaher stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the sale, the senior vice president now owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now owns 19,726 shares in the company, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,957 shares of company stock worth $8,265,802. 10.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Danaher

A number of large investors have recently modified their holdings of the company. Norges Bank acquired a new position in shares of Danaher during the fourth quarter valued at about $1,752,382,000. Wellington Management Group LLP boosted its stake in Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock valued at $6,185,203,000 after purchasing an additional 3,905,449 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in Danaher by 214.4% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 3,073,661 shares of the conglomerate’s stock worth $711,051,000 after purchasing an additional 2,096,038 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after purchasing an additional 1,619,586 shares during the last quarter. Finally, Capital International Investors lifted its holdings in shares of Danaher by 9.1% in the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock valued at $3,691,735,000 after purchasing an additional 1,334,781 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.